MMP2 and prostate carcinoma: To elucidate whether L1CAM shRNA-mediated suppression of invasive phenotypes was associated with changes in MMPs, the expression and enzymatic activity of MMP-2 and MMP-9, which is associated with clinical disease progression to bone metastasis in prostate cancer patients [30], were determined in genetically modified PC3 cells.